GBMA welcomes the ‘a’ flagging of biosimilar infliximab

The Generic and Biosimilar Medicines Association has welcomes the recommendation by the PBAC to list biosimilar infliximab (Inflectra) on the PBS and to recommend the marking as equivalent, also known as “a” flagging, of Inflectra with the reference product, Remicade. “PBS savings and improved patient access can only be realised if the use of biosimilars